, p < 0.001) and p < 0.001), and to a lesser extent with LVMI (r = 0.296, p = 0.005), p = 0.013). But in controls, it correlated only modestly with age (r = 0.304, p = 0.024), hemoglobin (r = 0.371, p = 0.005), high density lipoprotein cholesterol (r = 0.315, p = 0.019) and LVMI (r = 0.277, p = 0.043). Conclusions: It seems that in dialysis patients, adiponectin modest correlation with anthropometric measurements suggests an ongoing catabolic process rather than a change in ventricular function. (Cardiol J 2018; 25, 4: 501-511) 
Introduction
Adiponectin, an adipocyte-derived hormone, is a serum protein produced by the adipose tissue [1, 2] , and exerts anti-inflammatory, anti-diabetic and anti-atherosclerotic properties [3] [4] [5] [6] , and hence is considered a cardio-protective marker. Several previous studies suggested a possible influence of adiponectin in many clinical conditions, such as obesity, insulin resistance, hypertension, dyslipidemia and atherosclerotic heart disease [7] [8] [9] [10] [11] . Hypoadiponectinemia has been identified as independent risk factor for cardiovascular (CV) disease [12, 13] . Adiponectin prevents progression of left ventricular (LV) hypertrophy (LVH) [4, 14] , which correlates with CV complications both in hypertensive [15, 16] and chronic kidney disease (CKD) [17, 18] . While, it was found to normally correlate with blood pressure values, such a relationship in hypertensives remains controversial [11, [19] [20] [21] [22] . On the other hand, adiponectin levels have been found to correlate with LV mass index (LVMI) [4, 23] , and with impaired renal function [24] [25] [26] , in patients with renal failure and those treated with dialysis, although modestly [24, 27] . The aim in this study therefore, was to investigate the relationship between adiponectin and LV structure and function measurements in dialysis patients, as an attempt to get more insight into its protective CV role in these patients.
Methods

Patients
Eighty-nine consecutive patients treated with regular dialysis at the Dialysis Unit of the University Clinical Centre of Kosovo were included in this study (age 56 ± 13 years, 43% male) and 55 subjects, who had normal renal function, and served as a control group which was recruited between May 2013 and April 2016. All subjects gave informed consent to participate in the study, which was approved by the Ethics Committee of Medical Faculty, University of Prishtina. All patients included had been receiving chronic standardized dialysis 500-750 mL/min dialysate flow, 250-300 mL/min blood flow, over 3-4 h session, 3 times per week, for at least 6 months prior to recruitment in the study. The dialysis potassium level was 2.0 mEq/L and calcium level was 1.75 mEq/L. Patients with active malignancy, decompensated heart failure, hepatic or pulmonary disease, pregnant women and those with failed transplant were excluded from the study. Blood pressure was recorded with a brachial sphygmomanometer after subjects had rested in the supine position for at least 10 min.
Clinical data
For all participants, demographic details, physical examination and anthropometric measurements were taken. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, and/or diastolic blood pressure ≥ 90 mm Hg, or when patients were using antihypertensive therapy. Diabetes was defined as fasting plasma glucose ≥ 126 mg/dL (> 7 mmol/L) or the use of hypoglycemic medications. Body mass index (BMI) was measured after the dialysis session and was calculated by dividing dry weight by body height (kg/m 2 ). Twelve lead electrocardiogram was also recorded in all patients and QRS duration was measured.
Blood analysis
Blood urea nitrogen, creatinine, albumin, total protein, total cholesterol, triglyceride, calcium, phosphate, iron, hematocrit and hemoglobin were measured using standard methods. High density lipoprotein cholesterol (HDL-L) was measured by homogeneous enzymatic colorimetric assay (COBAS INTEGRA ® 400 plus, Roche), parathyroid hormone by immunoassay (COBAS e 411 analyzerRoche) and C-reactive protein (CRP) by particle enhanced turbidimetric assay (COBAS INTEGRA ® 400 plus, Roche). All samples for a given assay were tested simultaneously, in duplicate and in appropriate dilutions, according to conventional protocols.
Adiponectin measurement
Venous blood samples were withdrawn from each subject after ≥ 8 h of fasting. The samples were stored at -80°C until analyzed. Serum adiponectin concentration was measured by ELISA Microplate Reader Gea Linear. Intra-and interassay coefficient of variation was below 3.0% and 5.1%, respectively [28] .
Cardiac structure and function:
Left ventricular structure measurements. Echocardiographic examination in all patients and in controls was performed on the same day of dialysis using a Philips iE33 system with a multifrequency transducer and harmonic imaging as appropriate. Images were obtained with the patient in the left lateral decubitus position and during quiet expiration. LV volumes and ejection fraction (EF) were calculated from the apical 2-and 4-chamber views using the modified Simpson method. Left ventricular mass (LVM) was estimated using the anatomically validated formula of Devereux et al. [29, 30] and was indexed to height 2.7 (LVMI) [31] :
) + 0.6 [30] . LVH was defined as a LVMI of 47 g/m 2.7 for women and 53 g/m 2.7 for men [32] . LVM normalized for body surface area (LVM/BSA) was also calculated as g/m 2 . Left ventricular function measurements. From the spectral wave Doppler LV filling, peak E wave velocity, peak A wave velocity, the ratio between peak E and A velocities (E/A ratio), and E wave deceleration time were measured. From tissue-Doppler imaging recordings, peak systolic (s'), Afrim Poniku et al., Adiponectin in hemodialysis patients and early diastolic (e') and late diastolic (a') mitral annular velocities were also measured. The ratio of trans-mitral to myocardial early diastolic peak velocity (E/e') was calculated, after averaging septal and lateral e'velocities [33, 34] , to reflect filling pressures. Mitral annular plane systolic excursion (MAPSE) was measured by placing the M-mode cursor at the lateral and septal angles.
Total LV filling time (FT) was measured from the onset of the E wave to the end of the A wave and ejection time (ET) from the onset to the end of the aortic Doppler flow velocity. Total isovolumic time (t-IVT) was calculated as 60 -(total ET + total FT) and was expressed in s/min [35] . Tei index was calculated as the ratio between t-IVT and ET [36] . LV isovolumic relaxation time (IVRT) was measured as the time interval between LV end-ejection (from the pulsed-wave Doppler recording of the outflow tract velocity) and the onset of transmitral E-wave velocity.
The diameter of the LV outflow tract (LVOT) was measured from the parasternal long axis view as the distance between the bases of the aortic valve cusp during systole. The LVOT area was then calculated using the formula: LVOT area = = [(LVOT diameter average/2) 2 ] × 3.14. The average velocity time integral (VTI) was measured using the pulsed wave Doppler samples obtained at the center of the LVOT from the apical view. The stroke volume was calculated as the product of the LVOT area and the VTI of the LVOT blood flow.
Left atrial (LA) measurements. LA diameter was measured from aortic root recordings with the M-mode cursor positioned at the level of the aortic valve leaflets. LA volumes were measured using area-length method from the apical four chamber views, according to the guidelines of the American Society of Echocardiography and European Association of Echocardiography [22, 37] . Left atrial maximal volume (LAV max) was measured at the end of LV systole, just before the opening of the mitral valve, LA minimal volume (LAV min) was measured at end diastole, immediately after mitral valve closure. LA total emptying fraction was calculated using the formula [38] : LA total emptying fraction = LAV max -LAV min/LAV max × 100.
Statistical analysis
Values are expressed as means ± standard deviation. Differences between the two groups were analyzed using the unpaired Student t test following the analysis of variance. P values < 0.05 were considered statistically significant. The c 2 test was used to compare the categorical variables. Pearson correlations were performed to identify the simple correlations between adiponectin and the other variables. Subjects were stratified into four groups based on the dialysis treatment and on the presence of LVH on the echocardiographic examination: Group 1 (dialysis patients with LVH), Group 2 (dialysis patients without LVH), Group 3 (non-dialysis patients with LVH) and Group 4 (non-dialysis patients without LVH). A one-way ANOVA with Bonferroni correction was performed to compare continuous variables. All analyses were performed using SPSS 22 for windows.
Results
Clinical data of dialysis patients versus controls (Table 1) The baseline demographic, anthropometric and clinical data of dialysis patients and controls are shown in Table 1 . The age, gender and CV risk factors (smoking, diabetes, arterial hypertension and cholesterol level) were not different between groups. The dialysis patients had lower BMI and lower BSA (p < 0.001 for both), smaller waist measurements (p < 0.001), smaller interhip distance (p = 0.002), lower waist/hip ratio (p = 0.005), higher SBP and DBP (p = 0.002 and p = 0.018, respectively), higher baseline heart rate, higher CRP level, lower red blood cell (RBC), lower hemoglobin, lower albumin level, lower hematocrit and higher adiponectin level (p < 0.001, for all), lower blood iron level (p = = 0.028), and higher fasting glucose (p = 0.005) compared to controls. Less dialysis patients were treated with beta-blockers (p < 0.001), and more treated with angiotensin converting enzyme inhibitors (p = 0.003) and calcium antagonists (p < 0.001), compared to controls.
Cardiac function of dialysis patients versus controls (Table 2)
Dialysis patients had higher LVMI (p < 0. 
Dialysis patients with LVH versus without LVH (Tables 3, 4)
In addition to the increased LVM and LVMI, the dialysis patients with LVH had lower weight, lower BSA, higher blood iron level, larger LV end diastolic volume, higher LVEF and LV stroke volume (p < 0.05, for all) compared to dialysis patients without LVH. All the other clinical, biochemical and echocardiographic indices were not different between the two groups. 
Dialysis patients with LVH versus non-dialysis patients with LVH (Tables 3. 4)
Dialysis patients with LVH, had higher adiponectin (Fig. 1) , lower HDL-C, lower hemoglobin and RBC, shorter LVET (p < 0.001, for all), lower weight/hip ratio, lower BMI and BSA, lower hematocrit, lower baseline heart rate and broader QRS complex (p < 0.05 for all), compared to non-dialysis LVH patients. All other clinical, biochemical and echocardiographic indices did not differ between the two groups. 
Relationship of adiponectin with clinical, biochemical and cardiac function indices
In dialysis patients versus controls (Table 5) In all study patients, adiponectin had strong correlation with LVMI (p < 0.001) (Fig. 2) . In dialysis patients, adiponectin had a strong correlation with anthropometric parameters (waist measures, BMI and BSA, p < 0.001, for all) (Figs. 3, 4) , good correlation with LVMI (p = 0.005) (Fig. 5) , but weak correlation with waist/hips ratio (p = 0.037) and with total cholesterol level (p = 0.013). On the Afrim Poniku et al., Adiponectin in hemodialysis patients Table 4 . Echocardiographic data of study subjects. 
Discussion
The findings of this study can be summarized as follows: dialysis patients had lower BSA and BMI compared to age and gender matched controls but did have a larger LV cavity with thicker walls, higher LVMI and broader QRS duration. In addition, they were more anemic and had higher adiponectin levels compared to controls. Finally, while in dialysis patients adiponectin strongly correlated with BMI, it only modestly correlated with LVMI and volumes. The only relevant relationship in controls was with LVMI, although to a lesser strength than with dialysis patients.
Data interpretation. As expected, dialysis patients had lower body weight and BMI consistent with an element of cachexia, which is well known in patients with chronic kidney disease [39] . The profound degree of LVH resulting in higher mass index, again is consistent with the commonly found hypertension in this condition [40] . Such changes in LV structure resulted in significant functional disturbances in the form of reduced subendo-Afrim Poniku et al., Adiponectin in hemodialysis patients cardial function reflected on the MAPSE and its myocardial velocities, enlargement of LV volume, lower ejection fraction and left atrial enlargement, typical to what is commonly seen in hypertensive LV disease without kidney failure [41] . Furthermore, the dialysis patients had some degree of dyssynchrony in the form of broader QRS, along with shorter ejection and filling times, caused by prolonged isovolumic times. The enlargement of LV volume could be interpreted on the basis of volume overload because of dialysis. Despite all these changes in LV structure and function adponectine did not seem to be related to any of them, except weakly with LVMI. Only few studies exist in the literature, that assessed a relationship between LVMI and adiponectin in dialysis patients. These studies include a small number of patients and their direct comparison with the present re-Cardiology Journal 2018, Vol. 25, No. 4 sults has limitations. Komaba et al. [4] included only diabetic patients with dialysis, and Amira et al. [42] found good correlation, whereas Ayerden Ebinç et al. [23] was the only study whose results were in line with ours, having found a weak correlation between adiponectin and LVMI in dialysis patients. The strongest relationship found herein was between adiponectin and BMI, which is a reliable measure of body fat. These results support the close relationship of adiponectin and its site of secretion, i.e. the adipose tissue, rather than with cardiac structure and function.
Limitations of the study
As suggested above, the potential effect of volume overload during dialysis on the LV causing cavity enlargement, this might also have affected left atrial size and LV filling velocities and timing, hence the lack of a relationship with adiponectine. Right heart structure and function in this analysis was not included which might have shed some light on potential relationships, although they are also likely to be affected by loading conditions.
Conclusions
Although adiponectin is an established cardioprotective marker, it does not seem to be related to cardiac structure and function parameters but only strongly to BMI suggesting an ongoing catabolic process associating dialysis.
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